tradingkey.logo

Embecta Corp

EMBC
查看詳細走勢圖
12.080USD
+0.160+1.34%
收盤 12/24, 13:00美東報價延遲15分鐘
706.63M總市值
7.38本益比TTM

Embecta Corp

12.080
+0.160+1.34%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.34%

5天

+1.60%

1月

-17.09%

6月

+23.01%

今年開始到現在

-41.50%

1年

-40.76%

查看詳細走勢圖

TradingKey Embecta Corp股票評分

單位: USD 更新時間: 2025-12-23

操作建議

Embecta Corp當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名54/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為持有。最高目標價16.67。中期看,股價處於下降通道。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Embecta Corp評分

相關信息

行業排名
54 / 208
全市場排名
136 / 4568
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 4 分析師
持有
評級
16.667
目標均價
+50.83%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Embecta Corp亮點

亮點風險
Embecta Corp. is a global medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. The Company has a portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It also sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. It sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It also sells safety insulin syringes. It distributes its products through a variety of channels, including retail, hospitals and pharmacies.
利潤高增長
公司淨利潤處於行業前列,最新年度總收入1.08B美元
高分紅
公司屬於高分紅公司,最新股息支付率38.36%
估值低估
公司最新PE估值7.29,處於3年歷史低位
機構減倉
最新機構持股58.75M股,環比減少0.01%
HACAX持倉
明星投資者HACAX持倉,最新持倉1.05K股

Embecta Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Embecta Corp簡介

Embecta Corp. is a global medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. The Company has a portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It also sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. It sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It also sells safety insulin syringes. It distributes its products through a variety of channels, including retail, hospitals and pharmacies.
公司代碼EMBC
公司Embecta Corp
CEOKurdikar (Devdatt)
網址https://www.embecta.com/

常見問題

Embecta Corp(EMBC)的當前股價是多少?

Embecta Corp(EMBC)的當前股價是 12.080。

Embecta Corp 的股票代碼是什麼?

Embecta Corp的股票代碼是EMBC。

Embecta Corp股票的52週最高點是多少?

Embecta Corp股票的52週最高點是21.230。

Embecta Corp股票的52週最低點是多少?

Embecta Corp股票的52週最低點是9.200。

Embecta Corp的市值是多少?

Embecta Corp的市值是706.63M。

Embecta Corp的淨利潤是多少?

Embecta Corp的淨利潤為95.40M。

現在Embecta Corp(EMBC)的股票是買入、持有還是賣出?

根據分析師評級,Embecta Corp(EMBC)的總體評級為持有,目標價格為16.667。

Embecta Corp(EMBC)股票的每股收益(EPS TTM)是多少

Embecta Corp(EMBC)股票的每股收益(EPS TTM)是1.636。
KeyAI